Zydus Cadila gets approval from USFDA for muscle relaxant injection


Drugfirm Zydus Cadila has received final approval from the US health regulator to market Cisatracurium BesylateInjection, a muscle relaxant given before general anaesthesia.

Zydus Cadila has received final approval from the US Food and Drug Administration (USFDA) to market Cisatracurium Besylate Injection USP in the strength of 20 mg (base)/10 mL (2 mg/mL) multiple-dose vial,Cadila Healthcare said in a regulatory filing on Wednesday.

The drug will be manufactured at Liva plant of Cadila Healthcare Ltd.

Zydus Cadila is a part of the Cadila Healthcare group.

The group now has 297 approvals and has so far filed over 390 abbreviated new drug applications (ANDAs) since the commencement of the filing process in FY 2003-04.

Shares of Cadila Healthcare, the listed entity of the group, were trading at Rs 377.60 apiece on BSE, 0.15 per cent lower against their previous close.

(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)

Dear Reader,

Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keeping you informed and updated with credible news, authoritative views and incisive commentary on topical issues of relevance.

We, however, have a request.

As we battle the economic impact of the pandemic, we need your support even more, so that we can continue to offer you more quality content. Our subscription model has seen an encouraging response from many of you, who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of offering you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practise the journalism to which we are committed.

Support quality journalism and subscribe to Business Standard.

Digital Editor

Business Standard is now on Telegram.
For insightful reports and views on business, markets, politics and other issues, subscribe to our official Telegram channel